Component-specific surface and physiological activity in bovine-derived lung surfactants

Notter, Robert H.; Wang, Z; Egan, Edmund A.; Holm, Bruce A.

doi:10.1016/s0009-3084(01)00197-9

Cited by 83 publications

(102 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As reviewed elsewhere [46,118,119], Infasurf® is a direct chloroform:methanol extract of large aggregate surfactant obtained by bronchoalveolar lavage from calf lungs. Survanta® is an extract of minced bovine lung tissue to which is added synthetic dipalmitoyl phosphatidylcholine (DPPC), tripalmitin, and palmitic acid.…”

Section: Clinical Exogenous Surfactant Drugsmentioning

confidence: 99%

Section: Activity and Inhibition Resistance Of Exogenous Surfactant Dmentioning

confidence: 99%

“…For example, the activity differences between CLSE and Survanta® in Figure 3 and Figure 4 relate primarily to differences in the content of SP-B in the two preparations [106,118,175]. Survanta has an SP-B content by ELISA of only 0.044% by weight relative to phospholipid, while CLSE (Infasurf®) has an SP-B content of 0.9% by weight that approaches that of lavaged whole surfactant [118]. SP-B is known to be the most active of the hydrophobic surfactant proteins in enhancing the adsorption, dynamic surface activity, and inhibition resistance of phospholipids [118,[176][177][178][179][180][181][182][183][184].…”

Section: Activity and Inhibition Resistance Of Exogenous Surfactant Dmentioning

confidence: 99%

“…SP-B is known to be the most active of the hydrophobic surfactant proteins in enhancing the adsorption, dynamic surface activity, and inhibition resistance of phospholipids [118,[176][177][178][179][180][181][182][183][184]. The addition of bovine SP-B or synthetic SP-B peptides to Survanta® significantly improves its surface and physiological activity towards that of Infasurf and whole surfactant [106,118,175] (Figure 5)‥ Despite its lack of SP-B, other active components such as SP-C in Survanta® allow it to have significant efficacy in some forms of ALI/ARDS as noted earlier (e.g., [130,131,133]). Treatment with Survanta® has not been found to give substantial improvements in adult patients with ARDS [137], but Category I exogenous surfactants with the complete mix of surfactant lipids and near-endogenous amounts of both SP-B and SP-C may prove to have increased efficacy.…”

Section: Activity and Inhibition Resistance Of Exogenous Surfactant Dmentioning

confidence: 99%

“…However, the 21 amino acid KL4 peptide is only a very rough structural analog to native SP-B, and advances in peptide molecular modeling and synthesis technology support the feasibility of preparing new SP-B peptides with significantly greater sequence and molecular folding specificity, and correspondingly higher activity ( [202][203][204] for review). The development of new synthetic SP-B peptides is particularly important for optimal synthetic exogenous surfactants given the greater activity of SP-B compared to SP-C in native surfactant noted earlier [118,[176][177][178][179][180][181][182][183][184]. In addition to peptide/protein components in new synthetic surfactants, it is also important to consider their lipid constituents.…”

Section: Examples Of Research On New Synthetic Exogenous Surfactamentioning

confidence: 99%

See 4 more Smart Citations

Surfactant for Pediatric Acute Lung Injury

Willson¹,

Chess²,

Notter³

2008

Pediatric Clinics of North America

View full text Add to dashboard Cite

SynopsisThis article reviews exogenous surfactant therapy and its use in mitigating acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) in infants, children, and adults. Biophysical and animal research documenting surfactant dysfunction in ALI/ARDS is described, and the scientific rationale for treatment with exogenous surfactant is discussed. Major emphasis is on reviewing clinical studies of surfactant therapy in pediatric and adult patients with ALI/ARDS. Particular advantages from surfactant therapy in direct pulmonary forms of these syndromes are described. Also discussed are additional factors affecting the efficacy of exogenous surfactants in ALI/ARDS, including the multifaceted pathology of inflammatory lung injury, the effectiveness of surfactant delivery in injured lungs, and composition-based activity differences among clinical exogenous surfactant preparations.

show abstract

Section: Clinical Exogenous Surfactant Drugsmentioning

confidence: 99%

Section: Activity and Inhibition Resistance Of Exogenous Surfactant Dmentioning

confidence: 99%

Section: Activity and Inhibition Resistance Of Exogenous Surfactant Dmentioning

confidence: 99%

Section: Activity and Inhibition Resistance Of Exogenous Surfactant Dmentioning

confidence: 99%

Section: Examples Of Research On New Synthetic Exogenous Surfactamentioning

confidence: 99%

See 3 more Smart Citations

Surfactant for Pediatric Acute Lung Injury

Willson¹,

Chess²,

Notter³

2008

Pediatric Clinics of North America

View full text Add to dashboard Cite

show abstract

Effect of Exogenous Surfactant (Calfactant) in Pediatric Acute Lung Injury<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Willson

Thomas

Markovitz

et al. 2005

JAMA

374

279

View full text Add to dashboard Cite

CUTE RESPIRATORY DISTRESS syndrome (ARDS) was originally termed the adult respiratory distress syndrome because it resembled the clinical picture of infant respiratory distress syndrome (IRDS), and both exhibited hyaline membranes at autopsy. 1,2 Avery and Mead 3 first reported that lung surfactant quantity and activity were abnormal in infants with IRDS and surfactant replacement has subsequently become standard therapy for premature infants at risk for or having IRDS. Petty and Ashbaugh 2 described qualitative and quantitative surfactant deficiencies in their initial description of ARDS and the subsequent scientific literature (recently reviewed by Notter 4) has supported the role of surfactant dysfunction in both ARDS and less severe acute lung injury (ALI). 5 Surfactant replacement in ARDS and ALI has been Author Affiliations and Participating Hospitals and Collaborating Investigators are listed at the end of this article. Financial Disclosures: Dr Willson has received research grants from ONY Inc (Amherst, NY). Dr Egan is president and equity owner of ONY Inc.

show abstract

KL₄‐surfactant prevents hyperoxic and LPS‐induced lung injury in mice

Kinniry

Pick

Stephens

et al. 2006

Pediatric Pulmonology

View full text Add to dashboard Cite

KL(4)-surfactant contains the novel KL(4) peptide, sinapultide, which mimics properties of the hydrophobic pulmonary surfactant protein SP-B, in a phospholipid formulation and may be lung protective in experimental acute respiratory distress syndrome/acute lung injury. Our objective was to determine the protective role of airway delivery of KL(4)-surfactant in murine models of hyperoxic and lipopolysaccharide (LPS)-induced lung injury and further explore the mechanisms of protection. For the hyperoxic injury model, mice exposed to 80% O(2) for 6 days received an intranasal bolus of vehicle, beractant, or KL(4)-surfactant on days 3, 4, 5, and 6 of the exposure, and lungs were evaluated on day 7. Mice in the LPS-induced lung injury model received an intratracheal bolus of LPS followed by an intranasal bolus of KL(4)-surfactant or control at 1, 3, and 19 hr post-LPS challenge, and lungs were evaluated after 24 hr. To explore the mechanisms of protection, in vitro assays were performed with human and murine endothelial cell monolayers, and polymorphonuclear leukocyte (PMN) transmigration in the presence or absence of KL(4)-surfactant or lipid controls was evaluated. Based on morphology, histopathology, white blood cell count, percentage of PMNs, and protein concentration in bronchoalveolar lavage fluid, our data showed KL(4)-surfactant, unlike vehicle or beractant, blocked neutrophil influx into alveoli and suppressed lung injury. Furthermore, in vitro assays showed KL(4)-surfactant decreased neutrophil transmigration at the endothelial cell level. KL(4)-surfactant decreased inflammation and lung permeability compared with controls in both mouse models of lung injury. Evidence suggests the anti-inflammatory mechanism of the KL(4)-peptide is through inhibition of PMN transmigration through the endothelium.

show abstract

Component-specific surface and physiological activity in bovine-derived lung surfactants

Cited by 83 publications

References 53 publications

Surfactant for Pediatric Acute Lung Injury

Surfactant for Pediatric Acute Lung Injury

Effect of Exogenous Surfactant (Calfactant) in Pediatric Acute Lung Injury<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

KL₄‐surfactant prevents hyperoxic and LPS‐induced lung injury in mice

Contact Info

Product

Resources

About

Component-specific surface and physiological activity in bovine-derived lung surfactants

Cited by 83 publications

References 53 publications

Surfactant for Pediatric Acute Lung Injury

Surfactant for Pediatric Acute Lung Injury

Effect of Exogenous Surfactant (Calfactant) in Pediatric Acute Lung Injury<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

KL4‐surfactant prevents hyperoxic and LPS‐induced lung injury in mice

Contact Info

Product

Resources

About

KL₄‐surfactant prevents hyperoxic and LPS‐induced lung injury in mice